CITF Research Results

CITF Research Results2021-02-24T12:46:09-05:00

Immune cell analysis reveals that the amount of SARS-CoV-2 in the blood is a strong predictor of mortality

As SARS-CoV-2 continues to cause worldwide mortality, it has become increasingly important to define molecular markers that can identify individuals at risk of developing severe COVID-19, and even death. This could help in determining early preventive measures for improved patient outcomes. In a recent pre-print and therefore not yet peer-reviewed, CITF-funded researchers Drs. Daniel Kaufmann, Andrés Finzi and Nicolas Chomont from the Université de [...]

March 30, 2021|Immune mechanism studies|

Using a glowing SARS-CoV-2 virus and mice to explain how antibodies protect from infection and severe disease

An international multisite research collaboration, including CITF-funded researcher Dr. Andrés Finzi from the Université de Montréal, used genetically modified mice that mimic COVID-19 disease in humans to study how antibodies from people who have recovered from COVID-19 could prevent severe disease in other people. The authors concluded that these antibodies were effective in not only blocking SARS-CoV-2 infection, but also in allowing mice infected [...]

March 30, 2021|Immune mechanism studies|

Weaker antibody response to first COVID-19 vaccine dose found in long-term care residents

New data stemming from a study in British Columbia evaluating the strength and magnitude of antibody responses following one dose of the Pfizer-BioNTech vaccine indicate that older adults generate a much weaker antibody response to one vaccine dose compared to younger adults. These findings (in preprint and therefore not yet peer reviewed) hail from a CITF-funded project led by Dr. Marc Romney at the [...]

March 25, 2021|Long-term care studies|

A new testing strategy for the prompt detection of SARS-CoV-2 variants of concern

As the pandemic continues to evolve, it has become increasingly important to systematically adapt testing capacities to detect all variants of concern. In a recently published article, CITF-funded researcher Dr. Marc Romney and his team at the University of British Columbia proposed a new testing strategy that can rapidly detect circulating variants, and which enabled them to uncover a large swath of cases of [...]

Why do some people experience mild COVID-19 symptoms and others have severe illness? Pre-existing antibodies could explain the range of COVID-19 illness

CITF-funded researcher Dr. Pascal Lavoie from the University of British Columbia and his collaborators are suggesting that the presence of antibodies to SARS-CoV-2 may not necessarily indicate a previous infection. Using highly sensitive tests, they discovered pre-existing antibodies to SARS-CoV-2 in many uninfected adults. The study was funded in part by the COVID-19 Immunity Task Force (CITF).   Since the beginning of the COVID-19 [...]

March 23, 2021|Immune mechanism studies|

A novel mechanism leading to blood clot formation found in severely ill COVID-19 patients

Dr. Ishac Nazy and the McMaster Platelet Immunology Laboratory have found some of the reasons behind why some patients with severe COVID-19 have blood clots. The team found that blood from critically ill COVID-19 patients contains molecules that can activate cells involved in blood clotting. This study was supported by the Canadian Institutes of Health Research (CIHR) and the COVID-19 Immunity Task Force (CITF). [...]

March 23, 2021|Immune mechanism studies|

Tracking and mapping new mutations of SARS-CoV-2 across the globe

Dr. Marc-André Langlois and his team at the University of Ottawa analyzed mutations in SARS-CoV-2 from December 2019 to December 2020, including the impact on virus biology, therapeutics and vaccine effectiveness. This study was supported by the Canadian Institutes of Health Research (CIHR) and the COVID-19 Immunity Task Force (CITF). In this pre-print, the authors present a retrospective metadata study of high frequency mutations, [...]

March 15, 2021|Other|

Passport to normal: CITF researcher Kumanan Wilson comments on the future of immunity passports

With vaccine coverage on the horizon, many people are starting to think about how to document immunization. In this article, CITF-funded researcher Dr. Kumanan Wilson from the University of Ottawa and the Bruyère Research Institute and colleague Colleen Flood from the University of Ottawa, discuss how SARS-CoV-2 immunization passports could work, the infrastructure required to operationalize them and potential barriers and limitations to their [...]

March 3, 2021|Other|
Go to Top